| 1 |
33981608 | Which Way to Choose for the Treatment of Metastatic Prostate Cancer: A Case Report and Literature Review. | 2021 |
1 |
| 2 |
22633317 | Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid. | 2014 Jan |
1 |
| 3 |
25075079 | Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial. | 2014 Aug |
1 |
| 4 |
22126137 | Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. | 2012 Feb |
2 |
| 5 |
22267850 | Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer? | 2012 |
1 |
| 6 |
18203529 | [Androgen-independent prostate cancer with bone metastasis successfully treated by intravenous administration of zoledronic acid and diethylstilbestrol diphosphate]. | 2007 Dec |
1 |
| 7 |
16076701 | Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. | 2005 |
1 |
| 8 |
15329105 | Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. | 2004 Sep |
1 |